AU2001245401A1 - Hydrazones and analogs as cholesterol lowering agents - Google Patents

Hydrazones and analogs as cholesterol lowering agents

Info

Publication number
AU2001245401A1
AU2001245401A1 AU2001245401A AU4540101A AU2001245401A1 AU 2001245401 A1 AU2001245401 A1 AU 2001245401A1 AU 2001245401 A AU2001245401 A AU 2001245401A AU 4540101 A AU4540101 A AU 4540101A AU 2001245401 A1 AU2001245401 A1 AU 2001245401A1
Authority
AU
Australia
Prior art keywords
hydrazones
analogs
lowering agents
cholesterol lowering
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001245401A
Inventor
Hirohiko Hasegawa
Julio C. Medina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharmaceuticals Co Ltd
Tularik Inc
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd, Tularik Inc filed Critical Sumitomo Pharmaceuticals Co Ltd
Publication of AU2001245401A1 publication Critical patent/AU2001245401A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
AU2001245401A 2000-03-01 2001-03-01 Hydrazones and analogs as cholesterol lowering agents Abandoned AU2001245401A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18624900P 2000-03-01 2000-03-01
US18604700P 2000-03-01 2000-03-01
US60186249 2000-03-01
US60186047 2000-03-01
PCT/US2001/006810 WO2001064646A2 (en) 2000-03-01 2001-03-01 Hydrazones and analogs as cholesterol lowering agents

Publications (1)

Publication Number Publication Date
AU2001245401A1 true AU2001245401A1 (en) 2001-09-12

Family

ID=26881726

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001245401A Abandoned AU2001245401A1 (en) 2000-03-01 2001-03-01 Hydrazones and analogs as cholesterol lowering agents

Country Status (3)

Country Link
US (1) US6605615B2 (en)
AU (1) AU2001245401A1 (en)
WO (1) WO2001064646A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7509277B1 (en) * 1998-04-24 2009-03-24 Starmine Corporation Security analyst estimates performance viewing system and method
US7509274B2 (en) * 2000-04-17 2009-03-24 Kam Kendrick W Internet-based system for identification, measurement and ranking of investment portfolio management, and operation of a fund supermarket, including “best investor” managed funds
US7597876B2 (en) * 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US7563433B2 (en) * 2007-01-11 2009-07-21 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
US7993626B2 (en) * 2007-01-11 2011-08-09 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
US7138412B2 (en) * 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
MXPA05010975A (en) 2003-04-16 2005-11-28 Hoffmann La Roche (6-(phenoxy)-pyrido`3,4-d! pyrimidin-2-yl)-amine derivatives as p38 kinase inhibitors for the treatment of inflammatoryy conditions such as rheumatois artritis.
KR100812586B1 (en) 2003-04-16 2008-03-13 에프. 호프만-라 로슈 아게 Quinazoline compounds useful as p38 kinase inhibitors
KR20060054410A (en) * 2003-08-01 2006-05-22 제네랩스 테크놀로지스, 인코포레이티드 Bicyclic imidazol derivatives against flaviviridae
US20050215626A1 (en) * 2003-09-25 2005-09-29 Wyeth Substituted benzofuran oximes
EP1809614B1 (en) * 2004-04-08 2014-05-07 TargeGen, Inc. Benzotriazine inhibitors of kinases
CA2578283A1 (en) 2004-08-25 2006-03-02 Targegen, Inc. Heterocyclic compounds and methods of use
CN101083992A (en) 2004-09-20 2007-12-05 泽农医药公司 Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CN101083982A (en) 2004-09-20 2007-12-05 泽农医药公司 Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
EP2269610A3 (en) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AR051091A1 (en) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
AR051092A1 (en) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA
WO2006034279A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
WO2006034512A2 (en) * 2004-09-23 2006-03-30 Bayer Pharmaceuticals Corporation Phenyl-substituted quinoline and quinazoline compounds for the treatment of diabetes
BRPI0516110A (en) 2004-10-13 2008-08-26 Ptc Therapeutics Inc senseless suppression compounds and methods for their use
MX2007008587A (en) * 2005-01-14 2007-09-07 Genelabs Tech Inc Indole derivatives for treating viral infections.
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
BRPI0606172A2 (en) * 2005-06-08 2009-06-02 Targegen Inc methods and compositions for treating eye disorders
AU2006285278B2 (en) * 2005-08-31 2011-05-12 Immunomedics, Inc. F-18 peptides for pre targeted positron emission tomography imaging
JP5191391B2 (en) * 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
CN101400678A (en) 2006-01-23 2009-04-01 沃泰克斯药物股份有限公司 Thiophene-carboxamides useful as inhibitors of protein kinases
EP1991540A1 (en) * 2006-02-21 2008-11-19 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
AU2007223801A1 (en) * 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
JP2009533452A (en) 2006-04-13 2009-09-17 バーテックス ファーマシューティカルズ インコーポレイテッド Thiophene-carboxamides useful as inhibitors of protein kinases
CA2653005A1 (en) 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
US8853244B2 (en) 2006-05-23 2014-10-07 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
US8889100B2 (en) 2007-01-11 2014-11-18 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US8153100B2 (en) * 2007-01-11 2012-04-10 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
US8709382B2 (en) 2007-01-11 2014-04-29 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US8545809B2 (en) 2007-01-11 2013-10-01 Immunomedics, Inc. Methods and compositions for improved 18F labeling of proteins, peptides and other molecules
NZ598516A (en) 2009-09-03 2013-02-22 Bristol Myers Squibb Co Quinazolines as potassium ion channel inhibitors
JP5789821B2 (en) 2009-12-04 2015-10-07 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN106986863B (en) 2012-04-24 2019-12-31 沃泰克斯药物股份有限公司 DNA-PK inhibitors
RS62233B1 (en) 2012-07-11 2021-09-30 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
CN105246883B (en) 2013-03-12 2017-07-21 沃泰克斯药物股份有限公司 DNA PK inhibitor
PL3424920T3 (en) 2013-10-17 2020-11-16 Vertex Pharmaceuticals Incorporated Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors
ES2924111T3 (en) 2013-10-25 2022-10-04 Blueprint Medicines Corp Fibroblast growth factor receptor inhibitors
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
CN107400084B (en) * 2016-05-19 2020-04-10 南京理工大学 Method for synthesizing quinoline derivative
US11110108B2 (en) 2016-09-27 2021-09-07 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5852635A (en) * 1981-09-24 1983-03-28 Ricoh Co Ltd Lithographic original plate
US4728668A (en) 1985-04-16 1988-03-01 Usv Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
DE3903990A1 (en) 1989-02-10 1990-08-30 Basf Ag PHENYL HYDRAZONE, THEIR MANUFACTURE, AND MEDICAMENTS AND COSMETICS PRODUCED FROM THEM
DE4033808A1 (en) 1990-04-11 1991-10-17 Bayer Ag NAPHTHALINE DERIVATIVES
US5234936A (en) * 1991-10-24 1993-08-10 American Home Products Corporation Pyrimidocycloalkanes as a ii antagonists
JPH06130434A (en) 1992-10-19 1994-05-13 Hoechst Japan Ltd Organic nonlinear optical material
JPH07316144A (en) 1994-03-29 1995-12-05 Sankyo Co Ltd Diphenylmethylpiperazine derivative
JP3964478B2 (en) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 Heterocycle-containing carboxylic acid derivative and pharmaceutical containing the same
US6121309A (en) * 1996-03-18 2000-09-19 Eisai Co., Ltd. Fused-ring carboxylic acid derivatives

Also Published As

Publication number Publication date
WO2001064646A2 (en) 2001-09-07
US6605615B2 (en) 2003-08-12
WO2001064646A3 (en) 2002-05-30
US20010056096A1 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
AU2001245401A1 (en) Hydrazones and analogs as cholesterol lowering agents
AU2002216470A1 (en) Cholesterol lowering supplement
HK1057895A1 (en) Polyarylcarboxamides useful as lipid lowering agents
AU3215500A (en) Compounds and methods
HK1073310A1 (en) Biphenylcarboxamides useful as lipid lowering agents
AU2001280599A1 (en) Compounds and methods
AU2002214284A1 (en) Anti-helicobacterial agents
AU2001253418A1 (en) Compounds and methods
AU4439701A (en) Patient support
EP1151667A3 (en) Plant-activating agent
AU2001233208A1 (en) Human sulfatases
AU2001243394A1 (en) Compounds and methods
AU2002221131A1 (en) Blood lipid ameliorant composition
AUPQ872300A0 (en) Compounds and methods
AU1554301A (en) Radioprotecting agent
AU2001263850A1 (en) Pyrimidine-sulfonamides having endothelin-antagonist activity
AU1321101A (en) Cholesterol lowering and blood lipids lowering composition
AU2001273903A1 (en) Therapeutic agents
AU2001278951A1 (en) Compounds and methods
AU2001231107A1 (en) Improved lactational
HK1050316A1 (en) Cholesterol lowering agent
AU7308300A (en) Agents for reducing cholesterol-uptake and liquid-uptake
AU2001275696A1 (en) Therapeutic agent
AU2002235277A1 (en) Compounds and methods
AU2002221130A1 (en) Blood lipid ameliorant composition